Anzeige
Mehr »
Login
Mittwoch, 19.03.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Nachhaltig und revolutionär - Diese Innovation könnte der nächste Tesla-Moment für Investoren sein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DZZ0 | ISIN: US00941Q2030 | Ticker-Symbol: 4AR
Stuttgart
19.03.25
11:38 Uhr
0,530 Euro
-0,340
-39,08 %
Branche
Dienstleistungen
Aktienmarkt
ASIEN
1-Jahres-Chart
AIRNET TECHNOLOGY INC ADR Chart 1 Jahr
5-Tage-Chart
AIRNET TECHNOLOGY INC ADR 5-Tage-Chart
GlobeNewswire (Europe)
36 Leser
Artikel bewerten:
(0)

AirNet Technology Inc.: AirNet Granted Additional 180-Day Grace Period to Regain Compliance with Nasdaq Bid Price Requirement

Finanznachrichten News

BEIJING, March 18, 2025 (GLOBE NEWSWIRE) -- AirNet Technology Inc. ("AirNet" or the "Company") (Nasdaq: ANTE), is pleased to announce that Nasdaq has granted the Company an additional 180-day grace period, until September 15, 2025, to regain compliance with the Nasdaq Capital Market's minimum $1.00 bid price per share requirement.

AirNet remains fully committed to addressing the bid price deficiency during this extended compliance period. If the Company's closing bid price meets or exceeds $1 per ADS for a minimum of 10 consecutive business days within this timeframe, the Company will be in compliance with that requirement and Nasdaq should close this matter.

The Company has demonstrated compliance with all other applicable Nasdaq continued listing requirements, including the market value of publicly held shares and shareholder equity thresholds.

To ensure compliance, AirNet intends to monitor its ADS price closely and will take all necessary steps to maintain its Nasdaq listing, including effecting an ADS ratio change or reverse stock split.

Forward-Looking Statement

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F and its Current Reports on Form 6-K. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

Company Contact

Penny Pei
Investor Relations
AirNet Technology Inc.
Tel: +86-10-8460-8678
Email: penny@ihangmei.com


© 2025 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.